GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Structure Therapeutics Inc (NAS:GPCR) » Definitions » ROC %

Structure Therapeutics (Structure Therapeutics) ROC % : -998.29% (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Structure Therapeutics ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Structure Therapeutics's annualized return on capital (ROC %) for the quarter that ended in Mar. 2024 was -998.29%.

As of today (2024-05-24), Structure Therapeutics's WACC % is 10.41%. Structure Therapeutics's ROC % is -1358.96% (calculated using TTM income statement data). Structure Therapeutics earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Structure Therapeutics ROC % Historical Data

The historical data trend for Structure Therapeutics's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Structure Therapeutics ROC % Chart

Structure Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
ROC %
-1,282.65 -1,392.29 -824.28 -906.50

Structure Therapeutics Quarterly Data
Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,404.84 -3,386.65 -1,504.90 -987.69 -998.29

Structure Therapeutics ROC % Calculation

Structure Therapeutics's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2023 is calculated as:

ROC % (A: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2022 ) + Invested Capital (A: Dec. 2023 ))/ count )
=-102.775 * ( 1 - -0.26% )/( (8.56 + 14.174)/ 2 )
=-103.042215/11.367
=-906.50 %

where

Structure Therapeutics's annualized Return on Capital (ROC %) for the quarter that ended in Mar. 2024 is calculated as:

ROC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=-128.06 * ( 1 - -0.11% )/( (14.174 + 11.51)/ 2 )
=-128.200866/12.842
=-998.29 %

where

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Structure Therapeutics  (NAS:GPCR) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Structure Therapeutics's WACC % is 10.41%. Structure Therapeutics's ROC % is -1358.96% (calculated using TTM income statement data). Structure Therapeutics earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Structure Therapeutics ROC % Related Terms

Thank you for viewing the detailed overview of Structure Therapeutics's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Structure Therapeutics (Structure Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
611 Gateway Boulevard, Suite 223, South San Francisco, CA, USA, 94080
Structure Therapeutics Inc is a clinical-stage global biopharmaceutical company aiming to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small-molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073 and LTSE-2578.
Executives
Ted W Love director C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT, SUITE 101, SOUTH SAN FRANCISCO CA 94080
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Partners L P/il 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Inc/il 10 percent owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Fund Ii Lp other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Mark N Lampert 10 percent owner 1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Trading Fund Os Lp other: See Explanation of Responses P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Bvf Partners Os Ltd. other: See Explanation of Responses P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Bvf Gp Holdings Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf I Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Ii Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Melita Sun Jung officer: Chief Business Officer C/O STRUCTURE THERAPEUTICS INC., SOUTH SAN FRANCISCO CA 94080
Yingli Ma officer: Chief Technology Officer C/O STRUCTURE THERAPEUTICS INC., 611 GATEWAY BLVD., SUITE 223, SOUTH SAN FRANCISCO CA 94080
Joanne Waldstreicher director C/O STRUCTURE THERAPEUTICS INC., 611 GATEWAY BLVD, SUITE 223, SOUTH SAN FRANCISCO CA 94080
Jun Yoon officer: Chief Financial Officer C/O STRUCTURE THERAPEUTICS INC., 611 GATEWAY BLVD, SUITE 223, SOUTH SAN FRANCISCO CA 94080

Structure Therapeutics (Structure Therapeutics) Headlines